scholarly journals The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies

2020 ◽  
Vol 36 (1) ◽  
pp. 3-8
Author(s):  
Justin P. Reinert ◽  
Nathan J. Reinert
Keyword(s):  
Clinical Investigation ◽  
Healthcare Providers ◽  
Phosphodiesterase 5 Inhibitors ◽  
Disease States ◽  
High Altitude Pulmonary Edema ◽  
Unique Nature ◽  
Pulmonary Arterial ◽  
Traditional Therapies ◽  
Phosphodiesterase 5

Coronavirus Disease 2019 (COVID-19) has had a devastating impact on the ability of highly trained healthcare providers to render sufficient care, due to both the significant demand on resources and the unique nature of this disease that make it resistant to traditional therapies. This review sought to determine the potential role of phosphodiesterase-5 inhibitors (PDE-5) in the management of COVID-19 by extrapolating relevant data and clinical studies from other related disease states, including acute respiratory distress syndrome, acute lung injury, and high altitude pulmonary edema. Following a literature search, 4 reports were analyzed and included in this review. While the heterogenicity of data and the small number of trials included limit the interpretation and applicability, it was consistently demonstrated that PDE-5 inhibitors lowered pulmonary arterial pressures. The overall benefit of these agents is seemingly dependent upon the etiology of the respiratory failure, which warrants expanded clinical investigation for COVID-19.

Management of Benign Prostatic Hyperplasia: Role of Phosphodiesterase-5 Inhibitors

Drugs & Aging ◽  
2014 ◽  
Vol 31 (6) ◽  
pp. 425-439 ◽  
Author(s):  
M. Gacci ◽  
M. Carini ◽  
M. Salvi ◽  
A. Sebastianelli ◽  
L. Vignozzi ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Phosphodiesterase 5 Inhibitors ◽  
Phosphodiesterase 5

scholarly journals RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors

2017 ◽  
Vol 50 (3) ◽  
pp. 1602425 ◽  
Author(s):  
Marius M. Hoeper ◽  
Gérald Simonneau ◽  
Paul A. Corris ◽  
Hossein-Ardeschir Ghofrani ◽  
James R. Klinger ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Inadequate Response ◽  
Phosphodiesterase 5 Inhibitors ◽  
Pulmonary Arterial ◽  
Phosphodiesterase 5

scholarly journals Peyronie's Disease: Evolving Surgical Management and the Role of Phosphodiesterase 5 Inhibitors

2009 ◽  
Vol 9 ◽  
pp. 822-845 ◽  
Author(s):  
Tariq F. Al-Shaiji ◽  
Gerald B. Brock
Keyword(s):  
Tunica Albuginea ◽  
Surgical Techniques ◽  
Peyronie’S Disease ◽  
Surgical Approaches ◽  
Penile Curvature ◽  
Advantages And Disadvantages ◽  
Phosphodiesterase 5 Inhibitors ◽  
Peyronie's Disease ◽  
Phosphodiesterase 5

Peyronie's disease (PD) is a fibrotic disorder of the tunica albuginea of the penis. It is characterized by different degrees of penile curvature and sexual dysfunction. Several medical treatments have been employed to manage the disorder, with variable success rates. Surgical therapy is reserved for patients with severe penile deformity that fails to improve with medical treatment and impedes coital function. The advantages and disadvantages of various surgical approaches have long been debated. Herein, we describe the evolving surgical techniques for PD using knowledge obtained from the contemporary literature. In addition, we discuss the emerging data regarding the role of phosphodiesterase 5 inhibitors in the management of PD.

Sign in / Sign up

Export Citation Format

Share Document